相关实验视频

Updated: Sep 13, 2025

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

Pediococcus acidilactici CCFM6432在缓解主要抑郁症中无情感的有效性:一个随机对照试验

Du-Xing Li¹, Qi-Ming Hu², Chen-Chen Xu²

¹Department of Psychiatry, The Affiliated Mental Health Center of Jiangnan University, Wuxi 214151, Jiangsu Province, China.

World journal of psychiatry

|July 31, 2025

概括

Pediococcus acidilactici CCFM6432补充剂改善了主要抑郁症 (MDD) 患者的无情症症状. 这种益生菌增强了抗抑郁药的有效性,并显示了EEG生物标志物的积极变化,这表明了新的治疗途径.

科学领域:

神经科学是一个神经科学.
微生物学微生物学
精神病学是一个精神病学.

背景情况:

无情是主要抑郁症 (MDD) 的核心症状,通常对标准治疗无反应.
初步研究表明,Pediococcus acidilactici CCFM6432可能会减轻MDD患者的无情感.

研究的目的:

评价Pediococcus acidilactici CCFM6432在减少MDD患者无情症方面的疗效.
评估这种益生菌对无症的临床和脑电图 (EEG) 标记物的影响.

主要方法:

一项为期30天的随机对照试验,涉及MDD无情症患者.
参与者接受了标准抗抑郁药加Pediococcus acidilactici CCFM6432或安慰剂.
在基线和干预后进行了临床评估 (HAMD,TEPS) 和EEG (SPN,FRN幅度).

主要成果:

与安慰剂相比,Pediococcus acidilactici CCFM6432组在HAMD和TEPS得分上显示出显著的改善.
脑电图分析显示,益生菌组中SPN幅度增加,与抑郁症状减少相关.
在安慰剂组中没有观察到EEG生物标志物的显著变化.

结论:

辅助性Pediococcus acidilactici CCFM6432增强了对MDD的抗抑郁药物治疗.
这种益生菌有效地改善了MDD患者的无症症状.
Pediococcus acidilactici CCFM6432 显示了作为一种新型治疗的新药的潜力.

关键词:

这就是安赫多尼亚 (Anhedonia).抑郁症抑郁症抑郁症与事件相关的潜力与事件相关的潜力益生菌益生菌益生菌奖励加工是为了获得奖励.

更多相关视频

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Published on: January 7, 2019

相关概念视频

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Depressive Disorders: MDD and Dysthymia

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

Long-term Depression

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.